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Medication Related Osteonecrosis of the Jaw (MRONJ) is a rare adverse effect of a  
number of anti-resorptive and anti-angiogenic drugs that typically presents following a 
dental extraction. MRONJ is difficult to treat and can have a significant negative effect 
on quality of life, therefore the implementation of preventive measures is 
recommended. The multidisciplinary healthcare team should work to educate patients 
on the need for good oral hygiene and ensure that patients undergo remedial dental 
work prior to the initiation of implicated medications.    
As the medication experts in the multidisciplinary team, a key element of the 
pharmacist’s role is to educate both patients and other healthcare professionals on the 
safe and effective use of medications. This therefore represents an opportunity for 
pharmacists working in all settings to contribute to the prevention of MRONJ. 
This article provides a summary of the key background information in relation to the 
prevention of MRONJ and discusses the potential role of pharmacists working in 
community pharmacy, secondary care and in general practice.   
Keywords: Community Pharmacy, Interprofessional Working, Medication Related 
Osteonecrosis of the Jaw, MRONJ, Medication Safety, Prevention, Primary Care, Oral 
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Key Points 
 Medication Related Osteonecrosis of the Jaw (MRONJ) is a rare complication 
that typically presents following a dental extraction in some patients prescribed 
anti-resorptive or anti-angiogenic drugs; 
 MRONJ is challenging to treat and can have a significant negative effect of 
quality of life; 
  Patients should undergo remedial dental work prior to the initiation of 
implicated medicines and maintain good oral hygiene throughout treatment; 
 A multidisciplinary approach to the prevention of MRONJ is recommended, with 
pharmacists playing a key role in the education of patients on appropriate 
preventive measures; 
 Improved communication and interprofessional collaboration with medical and 
dental colleagues could improve patient outcomes.  
 
Oral health promotion has traditionally been the preserve of dental health 
professionals, but with the increasing recognition of the link between oral and general 
health, there is an increased importance in other health professionals promoting oral 
health. Wilson and Soni, the former and current president of the British Dental 
Association and Royal Pharmaceutical Society respectively, recently published an 
opinion piece in the British Dental Journal; emphasising the opportunities for pharmacy 
and dentistry to spearhead a new era of interprofessional healthcare, integrate 
dentistry into general healthcare provision and for example, collaborate to improve oral 
cancer screening, the management of diabetes and the oral health of patients in 
residential care homes(1).  
A key area of overlap between the two professions relates to the adverse effects of 
medication; there are a number of established adverse effects of medications which 
can impact negatively on patients’ oral health. These include xerostomia (dry mouth), 
taste disturbances, increased salivation, gingival overgrowth and osteonecrosis of the 
jaw(2-4).  
Case reports of osteonecrosis of the jaw linked to bisphosphonate therapy began to 
emerge in the early 2000s. Bisphosphonate-Related Osteonecrosis of the Jaw 
(BRONJ) is now well documented in the literature and has been subject to a number 
of Medicines and Healthcare products Regulatory Agency (MHRA) and European 
Medicines Agency (EMA) prescribing safety alerts(4-6). Although oral bisphosphonates 
remain the most commonly prescribed implicated agents, a number of other drugs 
which are used in the management of osteoporosis, Paget’s disease or in the 
treatment of cancer have subsequently been attributed to the potential development 
of osteonecrosis of the jaw (Table 1). This has led to a change in the terminology used 
to describe the condition which is now referred to as medication-related osteonecrosis 








Table 1. Drugs with MHRA Safety Updates for MRONJ at April 2017 
Bisphosphonates 

















































Drug Name Trade name (s) Indication 
bevacizumab Avastin (Roche) Cancer 
sunitinib Sutent (Pfizer) Cancer 
aflibercept Zaltrap (Sanofi) Cancer 
Reproduced, (with permission) from the Scottish Dental Clinical Effectiveness 
Programme(8). 
 
MRONJ is a complex phenomenon, and the official definition provided by the American 
Association of Oral and Maxillofacial Surgeons is as follows: 
“Exposed bone, or bone that can be probed through an intraoral or extraoral fistula, in 
the maxillofacial region that has persisted for more than eight weeks in patients with a 
history of treatment with anti-resorptive or anti-angiogenic drugs, and where there has 
been no history of radiation therapy to the jaw or no obvious metastatic disease to the 
jaws”(7). Figure.1 shows the intra-oral appearance of a patient with MRONJ. 
Insert Figure 1 about here 
Legend - Exposed necrotic bone is evident in the lower right region of the mandible, 
following extraction of the posterior teeth. Image courtesy of Dr F. Graziani and Dr 
Nisi 
The occurrence of MRONJ is thought to be related to the unique nature of the blood 
supply, structure and function of the jaw bones, and the microbiology of oral plaque 
biofilm in contributing to lesion development. The jaw bones (maxilla and mandible) 
have a high blood supply which may result in an increased concentration of implicated 
medicines in this area. Furthermore, alveolar bone (that part of the jaw bone which 
supports the teeth) remodelling occurs at a much higher rate than elsewhere in the 
skeleton (likely as a result of forces related to chewing and the presence of teeth) and 
thus there is a higher uptake of implicated medications in the alveolar bone compared 
with elsewhere in the body(9).  
It is difficult to provide precise prevalence rates for MRONJ, with varying reports 
published in the existing literature(8). The current consensus is that the estimated 
incidence of MRONJ in cancer patients treated with anti-resorptive or anti-angiogenic 
drugs is 1% and in osteoporosis patients treated with anti-resorptive drugs is 0.01-
0.1%(8). 
With an ageing population and a specific focus on the prevention of skeletal related 
events (SREs), the prescribing of oral bisphosphonates has increased considerably 
over recent years; in England prescribing data reveal 6,007,071 individual supplies of 
alendronic acid 70mg in 2018 compared with 2,841,358 in 2006(10,11). SREs, such as 
bone fractures, resulting from cancer that has metastasised to the bone are associated 
with significant morbidity and reductions in quality of life. Intravenous 
bisphosphonates, such as zoledronic acid and the monoclonal antibody denosumab 
are licenced for the prevention of SREs in osteoporosis and in patients with bone 
metastases.  
Prescribing rates of other drugs implicated in the development of MRONJ have also 
risen significantly in recent years and are expected to rise further. Prescribing of 
denosumab has increased with 52,210 individual supplies in England during 2018 
compared with 43,063 in 2017(10,11). The introduction of intravenous bisphosphonates 
in the treatment of early breast cancer has also been described as a risk for MRONJ 
development and approximates to a further 20,000 patients being prescribed 
bisphosphonates annually in the UK(12). The overall increase in prescribing of 
implicated medications is therefore likely to result in more patients becoming at risk of 
developing osteonecrosis of the jaw, making this rare condition a greater issue of 
concern in the context of clinical practice. 
Invasive dentoalveolar surgery, which includes commonly performed procedures such 
as tooth extractions, is the major risk factor in the development of MRONJ, with studies 
reporting that approximately 50-60% of patients with MRONJ identified tooth extraction 
as a specific precipitating event(7). The evidence supporting other risk factors is limited 
but these include concomitant corticosteroid use, poor oral hygiene, ill-fitting dentures, 
tobacco use and co-morbid conditions such as diabetes and anaemia(7).  
Diagnosis of MRONJ can be challenging, particularly for non-specialists and at-risk 
patients should be referred for general dental assessment and specific diagnosis and 
treatment intervention where necessary, as specified in the Summary of Product 
Characteristics for the major implicated drugs. The key signs and symptoms of 
MRONJ include: pain; exposed necrotic bone in the oral cavity; signs of infection such 
as fistula, swelling, cellulitis and pus exudation, tingling and numbness / pins and 
needles (hypoesthesia or paraesthesia) in the chin or lower lip, loosening of teeth 
(mobility) and bad breath (halitosis)(13). 
MRONJ is difficult to treat and can cause significant morbidity. A small study of 34 
patients with MRONJ utilising the Oral Health Impact Profile (OHIP-14), a validated 
and widely used oral health related quality of life indicator, found that the condition 
significantly (p<0.001) affects quality of life(14). Our previous qualitative study of 
patients diagnosed with MRONJ highlighted significant quality of life implications, 
particularly the physical, psychological and social impacts associated with the 
condition(15). This includes significant pain, regular use of analgesic medication and 
antibiotics, the need for invasive surgery, and the social anxiety of eating awkwardly 
in public. 
Due to the significant morbidity associated with MRONJ and the limited treatment 
options available, the elimination or stabilisation of oral disease before initiating 
antiresorptive agents is recommended as a preventive strategy for MRONJ in clinical 
guidelines(8). Therefore, it is important that patients are fully informed about the risk, 
the appropriate preventive strategies and signposted to dental services, preferably 
before these drugs are commenced. Studies have identified that dental screening and 
preventive strategies reduce the risk of osteonecrosis of the jaw. A study by 
Dimopoulous et al (2009), reported a statistically significant reduction in the incidence 
of MRONJ amongst multiple myeloma patients prescribed zoledronic acid following 
the implementation of preventive measures; the incidence rate before the 
implementation of preventive measures was 0.671/100 person-months and 0.230/100 
person-months afterwards [IR ratio 2.92, P = 0.029, 95% confidence interval 1.06-
8.03](16). Vandone et al (2012) also reported a 50% reduction in the incidence rate with 
screening and pre-treatment preventive dental care in patients with bone metastases 
from solid tumors prescribed iv bisphosphonates; osteonecrosis of the jaw was 
observed in 5.5% of patients (n= 11/200) not receiving preventive dental measures 
and 2.8% (n= 6/211) in those receiving preventive dental care before and during 
treatment with bisphosphonates(17). 
This represents an important opportunity for pharmacists in different settings to 
provide information to patients and healthcare professionals on the risk of and 
prevention of MRONJ. Evidence to support the current role of pharmacists in this 
regard is limited; a questionnaire of healthcare professionals in North Wales identified 
that only 11.8% of medical general practitioners (GPs) (n=120) and 9.7% of 
pharmacists (n=60) advised patients to alert their dentist to their use of 
bisphosphonates(18). A second small study (n=55) found that the majority of patients 
acquired knowledge about the drug they were prescribed from the patient information 
leaflets that are supplied with the medication (62%) with few patients (13%) receiving 
this information directly from their GP. When asked to identify side effects of 
bisphosphonate therapy, only 32% of patients receiving intravenous and 17% of 
patients receiving oral, bisphosphonates were aware of the potential risk of developing 
MRONJ(19). 
In our previous qualitative study of patients diagnosed with MRONJ participants 
described a perceived hierarchy in relation to the management of their health; they 
expected prescribers to utilise professional judgment on the suitability of the 
medication for them, and to provide information related to the adverse effects of 
medications. However, participants highlighted the importance of the pharmacist in 
reinforcing advice and were positive towards the pharmacist’s role in providing 
information on medications and conducting medication reviews(15). 
However, our previous qualitative study of GPs and pharmacists in North East England 
indicated that both professional groups had limited knowledge of both MRONJ and 
awareness of the recommended preventive strategies. Participants described the 
often complex medical histories of patients prescribed implicated medicines and that 
other aspects of patient care are frequently prioritised, overlooking the advice related 
to the risk and prevention of MRONJ(20).  
Our findings therefore suggest that patient safety continues to be compromised as 
patients’ are not receiving appropriate oral health advice and required preventive 
dental treatment before taking these implicated medications. 
There is however a significant challenge in effectively engaging patients in recognising 
the need for dental care; the most recent Adult Dental Health Survey (2009) identified 
that 23% of dentate adults do not attend the dentist at least every 2 years(21). Our 
previous qualitative study with patients also identified a number of barriers to dental 
care; including low priority of oral health care, patient’s phobia of dental treatment and 
the financial implications of dental care(15).  
There is, of course, significant literature supporting the role of the pharmacist in 
relation to the appropriate use of medicines and in multidisciplinary working(22). 
However, the literature is limited in relation to the role of the pharmacist in the delivery 
of oral health advice and in particular working interprofessionally with dental 
healthcare professionals. The prevention of MRONJ necessitates effective 
multidisciplinary working and represents an excellent opportunity for pharmacists in all 
settings to provide integrated, patient centred care. As the medication experts in the 
multidisciplinary team, a key component of the clinical pharmacists’ role should include 
education of other healthcare professionals on the safe and effective use of medicines 
and the risks of MRONJ; this includes the education and provision of clinical and 
medication advice to dentists, whom receive limited pharmacology and medication 
safety related education compared to pharmacists. This role not only relates to the 
prevention of MRONJ, but to the management of other new or established medications 
which can impact on oral health or the safe provision of dental treatment. It is important 
that adverse drug reactions are reported and this is another key role of pharmacists in 
all settings, particularly now that MRONJ is associated with medications other than 
bisphosphonates.  
Table 2 summarises the evidence base and the implications for clinical practice. 
Table 2. Summary of Evidence Base and Implications for Practice 
Evidence Base Implications for Practice 
MRONJ is a rare adverse effect of certain 
medications. Affecting approx. 1% of cancer 
patients prescribed anti-resorptive and anti-
angiogenic medication and 0.1% of patients 
prescribed anti-resorptive medication for 
osteoporosis(8). 
Pharmacists should be aware of the 
implicated medicines and therefore be 
in a position to provide appropriate 
preventive advice where appropriate. 
MRONJ is difficult to treat, therefore patients 
should undergo remedial dental treatment 
prior to initiating implicated medications(7-8). 
Patient newly prescribed implicated 
medicines should be referred to the 
dentist on prescribing. This advice 
should be supported by the 
interprofessional team, during 
prescribing and with subsequent supply 
of the medication 
Patients are at highest risk of developing 
MRONJ following a dental extraction(7-8). 
 
Patients should be advised to inform 
their dentist that they take implicated 
medications. Access to Summary Care 
Records should be considered for dental 
teams. 
Implicated medicines, such as 
bisphosphonates, have a number of 
complicated and important counselling 
points(26). 
Consideration should be made to the 
complexity of information and advice 
required when patients are prescribed 
these medications. More detailed 
counselling and time to discuss issues 
should be provided during consultations 
and inclusion of bisphosphonates in the 
NMS/MUR should be considered. 
The community pharmacist 
Community pharmacies are generally regarded as being easily accessible and, in 
many cases, provide the most frequent opportunity for patients to access a healthcare 
professional. Pharmacists in community settings have demonstrated an acceptance 
that oral healthcare can be part of their professional role and that the simple 
educational interventions can influence positive intentions in relation to the oral health 
habits of patients(23-24). 
Community pharmacists are unlikely to work with the implicated IV medications 
regularly, however, across the country, they dispense millions of prescriptions for oral 
bisphosphonates. The NMS is an advanced service within the NHS Community 
Pharmacy Contractual Framework, that supports patients newly prescribed medicines 
for long-term conditions; however the service specification does not currently include 
bisphosphonates(25). This is a missed opportunity; leaving the issue of MRONJ aside, 
this group of drugs has a number of issues that it would potentially benefit patients to 
be counselled about through an extended discussion and follow up with their 
pharmacist. The list of counselling points listed in the Summary of Product 
Characteristics (SPC) for alendronic acid is extensive and includes the following(26); 
take once per week; take on an empty stomach; a full glass of water (plain water); 30 
minutes before food, drink or medicine; avoid coffee, mineral water or juice; swallow 
whole; do not crush or chew; stay upright; do not lie down until you have eaten a meal; 
when to take your calcium supplements; oesophageal adverse effects; and finally if 
you haven’t forgotten everything else, look after your teeth and use in caution with 
poor dental health, gum disease or if requiring a dental extraction. 
The NMS would provide the pharmacist and the patient time to have a thorough 
discussion related to the administration instructions of the drug, but also facilitate an 
important discussion on the need to maintain good oral hygiene and oral health, and 
to visit the dentist before initiation. This represents an important opportunity to ensure 
that patients are signposted appropriately and that they are empowered to make 
informed decisions in relation to their treatment and lifestyle management. 
Like the NMS, the Medication Use Review (MUR) service does not specifically include 
bisphosphonates in the service specification(27). MURs are also part of the NHS 
Community Pharmacy Contractual Framework and provide patients with structured, 
adherence-centred, polypharmacy reviews. Although many patients prescribed 
bisphosphonates have complex needs and may be eligible for an MUR due to 
polypharmacy considerations, this is again a potential lost opportunity to reinforce 
preventive advice to patients.  
The clinical pharmacist in general practice 
The growth of the pharmacist’s role in general practice represents a significant 
opportunity to utilise the extensive knowledge base and skill set in relation to the safe 
and effective management of medications and long-term conditions. The Primary Care 
Pharmacy Association’s Clinical Pharmacist in General Practice Job Description 
details examples of duties and responsibility for pharmacists in this setting(28); this 
includes managing long-term conditions, performing medication use reviews, 
implementing medication safety guidance, supporting public health campaigns and 
signposting to appropriate healthcare professionals. 
Patients prescribed medications implicated in the development of MRONJ fall into 
many of these categories; pharmacists in this role have access to full medical records, 
often co-ordinate discharges from secondary care and the transfer of information 
between healthcare settings. Clinical pharmacists are experienced at taking accurate 
medication histories and have a key role in ensuring accurate documentation of all the 
medications that patients both historically and currently take. Medication may also be 
initiated by pharmacist independent prescribers and patients may have their 
medication reviewed as part of a chronic disease management clinic or be specifically 
identified as part of a targeted intervention.  
The evaluation of clinical pharmacists in general practice pilot studies by the University 
of Nottingham found that patients benefited from increased lifestyle advice and the 
provision of advice that improves medicines adherence, and reduces the adverse 
effects of medication(29). However, the delivery of oral health care education in this 
setting has not been particularly explored; pharmacists, commissioners, and 
researchers should be encouraged to be innovative and incorporate oral health advice 
as an integral part of their current roles. Practitioners should be aware of oral health 
issues and integrate these into their current practices where appropriate; for example, 
as part of the lifestyle advice that already forms part of medication reviews and chronic 
disease management clinics. 
Secondary care 
Many of the more recent medications to be implicated in the development of MRONJ 
are prescribed, dispensed and administered in secondary care settings(30). A referral 
service for dental screening from haematology and oncology clinics in Wales was 
established with over 90% of the patients referred for screening reporting satisfaction 
with the service(31). Such referral pathways could, and should, naturally incorporate 
specialist pharmacists involved in the care of higher risk oncology patients or those 
prescribed IV bisphosphonates or denosumab. 
Other roles in an acute setting include the management of patients after falls and 
fractures, medication reviews and discharge planning, and deprescribing medicines in 
line with clinical guidelines to reduce adverse drug effects, Long term therapy with 
bisphosphonates is associated with an increased risk of MRONJ and therefore 
represents a potential target for intervention. An interesting finding from our qualitative 
studies was that many patients were unclear on the duration of treatment with 
bisphosphonates with some patients having taken these medicines for many years(15). 
Other collaborative opportunities 
The prevention of MRONJ represents just a small proportion of the potential 
collaborative opportunities for pharmacists and dental care professionals. We know 
that 23% of the population do not attend for regular dental appointments and the ease 
of access to pharmacies represents a significant opportunity to engage this group of 
patients and work collaboratively with dentists as discussed by Wilson and Soni(1,21). 
Pharmacists already play a key role in the prevention of the oral adverse effects of 
inhaled medication, such as oral candidiasis and in the provision of smoking cessation 
services. 
A pilot oral health promotion intervention in County Durham showed that patients are 
receptive to oral health advice when provided by pharmacists; the pilot found that a 
brief intervention can result in positive intentions to change oral health behaviours(24).  
There is increasing evidence of a two-way relationship between periodontitis (gum 
disease) and diabetes; periodontitis is a chronic inflammatory disease caused by 
bacterial infection of the supporting tissues surrounding the teeth, which is usually 
painless and often goes unnoticed and untreated until it reaches an advanced 
stage(32). The Cochrane Collaboration published a review in 2015, highlighting that 
randomised controlled trials have demonstrated that periodontal therapy is associated 
with approximately a 3-4 mmol/mol (0.3-0.4%) reduction in HbA1c levels after 3 
months(33); this is a clinical impact equivalent to adding a second drug to a 
pharmacological regimen(34). Pharmacists, in all settings, see patients with diabetes 
regularly, and this represents an opportunity to target patients who can benefit 
significantly from oral health education. 
Cancer of the ‘mouth’ or oral cavity and ‘throat’ oropharyngeal cancer rank as the 
seventh most common cancers globally, with the highest incidence rates in males over 
the age of 60 years and patients living in deprived areas(35-36). A recent study of oral 
cancer in Scotland found that in the majority of diagnosed cases no contact had been 
made with a dentist in the 2 years preceding the diagnosis; the study concluded that 
early detection strategies in alternative settings should be explored(37) representing 
another opportunity to involve pharmacists. 
  
Conclusion 
In summary, MRONJ is a rare complication that typically presents following a dental 
extraction in some patients prescribed anti-resorptive or anti-angiogenic drugs; it is 
difficult to treat and can result in significant negative effects on quality of life. 
Pharmacists should be aware of this risk and the recommended preventive advice, 
which could be incorporated into current roles across the pharmacy sectors. Further 
exploration of the pharmacist’s’ role and interprofessional collaboration with medical 
and dental colleagues may also provide significant benefits to other patient groups, in 
which oral heath advice or interventions could potentially improve patient outcomes. 
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